Results 171 to 180 of about 522,910 (321)

The mortality for the implantable cardiac defibrillator in nonischemic cardiomyopathy: An updated systematic review and meta‐analysis

Clinical Cardiology, Volume 45, Issue 12, Page 1163-1170, December 2022., 2022
Abstract The implantable cardiac defibrillator (ICD) is common for the management of nonischemic cardiomyopathy (NICM). Mortality is a crucial issue for patients with NICM. We can understand the mortality events of ICD versus medicine treatment via a systemic review and meta‐analysis of randomized clinical trials.
Wenfeng He, Cheng Xue, Jiankang Zheng, Zhuang Shuai   +3 more
wiley   +1 more source

Materials for Placebo V.

, 1966
W. C. Watt
openalex   +1 more source

Outcome of Patients With Lupus Nephritis Treated With an Anti‐CD40 Monoclonal Antibody According to Kidney Biopsy Features

Arthritis &Rheumatology, EarlyView.
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo, Helmut Schumacher, Juergen Steffgen, Simone Deutschel, David Jayne, Ingeborg Bajema   +5 more
wiley   +1 more source

Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD

Clinical Cardiology, Volume 45, Issue 12, Page 1143-1146, December 2022., 2022
Abstract Background The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double‐blind, placebo‐controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER).
Marc P. Bonaca, Michael Szarek, E. Sebastian Debus, Mark R. Nehler, Manesh R. Patel, Sonia S. Anand, Eva Muehlhofer, Scott D. Berkowitz, Lloyd P. Haskell, Rupert M. Bauersachs   +9 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, Accepted Article.
Objectives Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The Phase III MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E Wechsler, Jared Silver, Gerhard Wolff, Robert G Price, Rejina Verghis, Peter F Weller, Peter A Merkel, Paneez Khoury, on behalf of the EGPA Mepolizumab Open‐Label Extension study group, Arnaud Bourdin, Pascal Chanez, Anoop Chauhan, Vincent Cottin, Gerald Gleich, Berhnard Hellmich, Tomonori Ishii, David Jayne, Jean‐Emmanuel Kahn, Peter Kern, Nader Khalidi, Ina Koetter, Carol Langford, Amy Markezich, Paul Monach, Shamsa Naveed, Peter Oelzner, Kenneth Pinna, Xavier Puechal, Emory H Robinette, Florence Roufosse, Reinhard Voll, Andrew Schafer, Kaharu Sumino, Masami Taniguchi, Phillip Lieberman   +34 more
wiley   +1 more source

Vascular co‐option and vasculogenic mimicry mediate resistance to antiangiogenic strategies

Cancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background The concept that all the tumors need the formation of new vessels to grow inspired the hypothesis that inhibition of angiogenesis would have led to “cure” cancer. The expectancy that this type of therapy would have avoided the insurgence of resistance was based on the concept that targeting normal vessels, instead of the cancer ...
Francesco Pezzella, Domenico Ribatti
wiley   +1 more source

Comparison of two doses of cimetidine and placebo in the treatment of duodenal ulcer: a multicentre trial. [PDF]

, 1979
Karna Dev Bardhan, Dominik Saul, Rotherham Hospital, John Edwards, Paul Smith, Llandough Hospital, M. R. Fettes, J. A. H. Forrest, R C Heading, Robert A. Logan, M W Dronfield, M J Langman, W Larkworthy, Nocton Hall, S J Haggie, J H Wyllie, Chris Corbett, H L Duthie, I Fussey, C.H. Holdsworth, G. V. Balmforth, Takashi Maruyama   +21 more
openalex   +1 more source

Evaluation of Deutetrabenazine's Potential to Delay Cardiac Repolarization Using Concentration‐QTc Analysis

Clinical Pharmacology in Drug Development, Volume 12, Issue 1, Page 94-106, January 2023., 2023
Abstract Deutetrabenazine (Austedo) is indicated in adults for chorea associated with Huntington disease and tardive dyskinesia. Escalating deutetrabenazine doses were administered to healthy volunteers who were cytochrome P450 2D6 extensive/intermediate metabolizers (EMs) or poor metabolizers (PMs) to determine pharmacokinetic exposure of parent drug ...
Frank Schneider, Borje Darpo, Pippa S. Loupe, Hongqi Xue, Helena Knebel, Maria Gutierrez, Mark Forrest Gordon, Laura Rabinovich‐Guilatt   +7 more
wiley   +1 more source

The Placebo Hypoalgesic Response Is Reduced in Healthy Older Adults Showing a Decline in Executive Functioning. [PDF]

J Pain Res
Rischer KM, Dierolf AM, Anton F, Montoya P, González-Roldán AM, van der Meulen M.   +5 more
europepmc   +1 more source